Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. - Wikidata - wikimedia - TriplyDB

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

http://www.wikidata.org/entity/Q37731326

about

Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2.Cancer-type dependent expression of CK2 transcripts.Therapeutic targeting of CK2 in acute and chronic leukemias.

P2860

Q33844943-260AAFBD-5478-40D1-A120-346CC815C4D4 Q42333696-8B7FD7B6-942F-4DA3-A0C6-A6A2CC74661F Q47114281-CE45E80C-BC05-47CA-8154-2CD55D217896 Q47677919-25057CD2-EB49-4FC0-BA8B-2DADCB74882D

P2860

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.

http://www.wikidata.org/entity/Q37731326

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@en

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@nl

type

label

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@en

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@nl

prefLabel

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@en

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@nl

P1433

Q37731326-22F6E30B-8421-4B07-AFBA-A2D168C6D648

P1476

Q37731326-D062EC00-D60A-408B-B0BD-9FE2FE8DA244

P2093

Q37731326-1044441C-C36A-474F-9FEE-74C9895C2E28

Q37731326-1291BD20-FFA5-419D-96BE-B50ECB54506F

Q37731326-2FA29BCA-0503-48AB-93A3-88499A531E7B

Q37731326-4494634A-D913-4095-A458-346E75ECFA64

Q37731326-825B3C13-C06F-418D-B7B1-8028ECFF105B

Q37731326-C3030284-0C15-4DEF-99EB-F0A21FB23209

Q37731326-E6466CB0-4188-4111-A753-3B99ACE76662

P2860

Q37731326-08C5E0A4-5946-43D4-AB38-C026D73835E3

Q37731326-0E289C7D-127C-4D59-AE48-BDDB0BAA3D79

Q37731326-0F2BB9EB-F1A2-462D-93EE-CAB515554D93

Q37731326-126757AE-4FD9-487B-B86B-6007EFF89EA2

Q37731326-16C65CD8-4AE7-4B3C-8D4E-05B7DD669151

Q37731326-189B5FA0-92EB-467D-AFDD-ABF80E9600A2

Q37731326-2B52E624-B560-4EC6-A892-273343C00CC3

Q37731326-2FE9719F-3F25-4AC7-93C1-2461AC9B0486

Q37731326-33614CFD-E64E-46EA-AC4F-8547227F4804

Q37731326-36391744-506E-44AE-8D77-BAF60A7FEE33

P31

Q37731326-1E084CF3-B672-4369-BABA-CEE3B251807E

P356

Q37731326-366A8EFE-8645-416A-B8B7-005C0BB450C0

P433

Q37731326-43A2C9A9-E10C-4A85-BD2E-BA391DCEA1C2

P478

Q37731326-63C4695F-4C7F-4753-A269-F1F831617573

P50

Q37731326-0DBCBBD0-12F1-4437-A72F-891B9880FC38

Q37731326-1010773B-0F5B-4CCD-84C5-3AC0F08AF06D

Q37731326-AF4C8677-9DE2-462D-9773-4CB7EABA898C

P577

Q37731326-28CAB9D3-3696-44B4-AB42-0809A2292E89

P698

Q37731326-04EEC719-F2E7-4C8D-8E44-8DEA9F84BB8E

P932

Q37731326-7D683E97-A6D1-4DAA-86FE-1C85BEA16511

P356

P1433

Pharmaceuticals

P1476

Targeting Protein Kinase CK2: ...... erapy in Immunocompetent Mice.

@en

P2093

Emilio Itarte

http://www.w3.org/2001/XMLSchema#string

Jordi Vilardell

http://www.w3.org/2001/XMLSchema#string

Laura Ferrer-Font

http://www.w3.org/2001/XMLSchema#string

Lorenzo A Pinna

http://www.w3.org/2001/XMLSchema#string

Lucia Villamañan

http://www.w3.org/2001/XMLSchema#string

Maria Plana

http://www.w3.org/2001/XMLSchema#string

Nuria Arias-Ramos

http://www.w3.org/2001/XMLSchema#string

P2860

Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes

Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells

Identification of a novel function of CX-4945 as a splicing regulator

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

P31

scholarly article

P356

10.3390/PH10010024

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28208677

http://www.w3.org/2001/XMLSchema#string

P932

5374428

http://www.w3.org/2001/XMLSchema#string